Neuroimaging in Clinical Assessment

On this page

Neuroimaging in Clinical Assessment - Brain Blueprints

Structural neuroimaging visualizes brain anatomy; key for ruling out organic causes.

  • Computed Tomography (CT)
    • Principle: X-ray based; measures tissue density.
    • Indications: Acute head trauma, suspected intracranial bleed, stroke.
    • Pros: Fast, accessible.
    • Cons: Radiation, less soft tissue detail than MRI.
  • Magnetic Resonance Imaging (MRI)
    • Principle: Magnetic fields & radio waves.
    • Indications: Detailed soft tissue, white/gray matter lesions.
    • Pros: Superior detail, no radiation.
    • Cons: Slower, costlier, metal contraindications.
    • Key Sequences:
      • T1-weighted: Anatomy (CSF dark). 📌 T1: Anatomy.
      • T2-weighted: Pathology (CSF bright). 📌 T2: H2O bright.
      • FLAIR: T2-like, CSF dark; highlights periventricular lesions (e.g., MS).

⭐ MRI is superior to CT for detecting subtle structural brain abnormalities, white matter lesions (e.g., multiple sclerosis), and early ischemic changes.

CT vs MRI Brain Scansoka

Neuroimaging in Clinical Assessment - Mind at Work

Functional neuroimaging provides dynamic insights into brain activity, blood flow, and neurochemistry.

  • Functional MRI (fMRI):
    • Measures brain activity by detecting changes in blood oxygenation (BOLD signal).
    • Non-invasive, no radiation. High spatial, moderate temporal resolution.
    • Uses: Cognitive research, mapping eloquent cortex pre-surgery.
  • Positron Emission Tomography (PET):
    • Visualizes metabolic processes (e.g., FDG for glucose metabolism) or receptor binding using radiolabeled tracers.
    • Involves ionizing radiation.
    • Uses: Alzheimer's (hypometabolism), Parkinson's (dopamine), oncology.

    ⭐ PET with 18F-FDG often reveals characteristic bilateral temporoparietal hypometabolism in Alzheimer's disease.

  • Single Photon Emission CT (SPECT):
    • Measures regional cerebral blood flow (rCBF) or neurotransmitter receptor availability.
    • Uses gamma-emitting radiotracers; less resolution and sensitivity than PET.
    • Uses: Dementia (perfusion), epilepsy (ictal vs. interictal), cerebrovascular disease.
  • Magnetic Resonance Spectroscopy (MRS):
    • Detects and quantifies brain metabolites (e.g., N-acetylaspartate (NAA), choline, creatine, lactate).
    • Non-invasive; provides biochemical information.
    • Uses: Differentiating tumor types, metabolic encephalopathies, research in mood disorders. Brain MRI scans on tablet

Neuroimaging in Clinical Assessment - Disorder Snapshots

  • Schizophrenia: ↑ Ventricular size (lateral, third); ↓ cortical volume (frontal, temporal); hypofrontality (DLPFC).
  • Major Depressive Disorder (MDD): ↓ Hippocampal volume; ↑ amygdala activity (negative stimuli); ↓ DLPFC activity (cognitive tasks).
  • Bipolar Disorder: ↑ White matter hyperintensities; ↓ prefrontal cortex volume; altered amygdala-prefrontal connectivity.
  • Obsessive-Compulsive Disorder (OCD): Orbitofrontal cortex (OFC), anterior cingulate cortex (ACC), striatal (caudate) abnormalities; functional: ↑ Cortico-Striato-Thalamo-Cortical (CSTC) loop hyperactivity.
  • Post-Traumatic Stress Disorder (PTSD): ↓ Hippocampal & ACC volume; ↑ amygdala reactivity (trauma cues); ↓ medial prefrontal cortex (mPFC) activation.
  • Alzheimer's Disease: Medial temporal lobe atrophy (hippocampus, entorhinal cortex); ↓ temporoparietal glucose metabolism (FDG-PET).
  • ADHD: ↓ Volume: prefrontal cortex, basal ganglia, cerebellum; hypoactivation in frontostriatal networks.

⭐ Ventricular enlargement (lateral ventricles) is a consistent structural MRI finding in schizophrenia.

Neuroimaging in Clinical Assessment - Lens Limitations

  • Supportive, Not Definitive: Rules out organic causes; not diagnostic for most psychiatric disorders.
  • Low Specificity/Sensitivity: For primary psychiatric conditions, limiting individual diagnostic use.
  • Incidental Findings: Can create anxiety, necessitate further costly investigations.
  • Cost & Access: Significant barriers to routine clinical application.
  • Research-Clinical Gap: Group findings often not applicable to individual patients.

    ⭐ Key role: Exclude organic mimics (e.g., tumor, stroke) in atypical psychiatric symptoms via CT/MRI.

  • Interpretation Variability: Subjectivity can impact reliability.

High‑Yield Points - ⚡ Biggest Takeaways

  • Structural neuroimaging (CT, MRI) primarily rules out organic causes of psychiatric symptoms.
  • MRI offers superior soft-tissue contrast over CT for detecting subtle brain changes.
  • Functional neuroimaging (fMRI, PET, SPECT) remains largely a research tool, not for routine psychiatric diagnosis.
  • SPECT/PET can visualize cerebral blood flow, metabolism, or neuroreceptor occupancy.
  • No pathognomonic neuroimaging findings exist for most primary psychiatric illnesses like schizophrenia or bipolar disorder.
  • Hippocampal atrophy on MRI may be associated with chronic depression or Alzheimer's disease.
  • Ventricular enlargement and cortical atrophy are non-specific findings sometimes observed in schizophrenia cases.
Rezzy AI Tutor

Have doubts about this lesson?

Ask Rezzy, our AI tutor, to explain anything you didn't understand

Practice Questions: Neuroimaging in Clinical Assessment

Test your understanding with these related questions

Which radiopharmaceutical is commonly used in positron emission tomography (PET) imaging?

1 of 5

Flashcards: Neuroimaging in Clinical Assessment

1/10

Mini-Mental State Examination (MMSE, also known as _____ test) is a score out of 30 and is used to measure cognitive impairment.

TAP TO REVEAL ANSWER

Mini-Mental State Examination (MMSE, also known as _____ test) is a score out of 30 and is used to measure cognitive impairment.

Folstein's

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start For Free
Neuroimaging in Clinical Assessment - Free Indian Medical PG